IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02

Story continues below

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d)

Appointment of Dr. Brett Monia to Board of Directors

On March 22, 2019, the Board of Directors (the “Board”) of Ionis Pharmaceuticals, Inc. (the “Company”) increased the size of the Board from ten directors to eleven directors and appointed Brett Monia, Ph.D, the Company’s Chief Operating Officer, to the Board to fill the resulting vacancy. Dr. Monia will serve on the Board’s Agenda Committee, effective immediately.

Since the beginning of the Company’s last fiscal year through the present, there have been no related person transactions between Dr. Monia and the Company, and there are currently no proposed related person transactions between Dr. Monia and the Company, within the meaning of Item 404(a) of Regulation S-K. There are no arrangements or understandings between Dr. Monia and any other persons to which Dr. Monia was appointed as a director of the Company.

A copy of the press release announcing the appointment of Dr. Monia is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

(e)

Amended and Restated Advisory Services Agreement between the Company and B. Lynne Parshall

As the Company previously reported on its Current Report on Form 8-K filed on January 16, 2018, B. Lynne Parshall, who was with the Company for 27 years and was the Company’s former Chief Operating Officer, became a Senior Strategic Advisor to the Company effective January 2018. The Company and Ms. Parshall entered into a Strategic Advisory Services Agreement on January 15, 2018 to reflect her new role (the “Advisory Services Agreement”). In 2018, Ms. Parshall performed significantly more services than originally expected. The Company thus agreed, with the approval of the Compensation Committee, to increase the amount of fees to be paid to Ms. Parshall commensurate with the amount of additional work performed and agreed that Ms. Parshall would be eligible for a bonus with a target of 30% of her fees with a personal performance factor and final bonus amount to be approved by the Compensation Committee.

On March 22, 2019, the Company and Ms. Parshall entered into an amendment and restatement of the Advisory Services Agreement (the “Amended and Restated Advisory Services Agreement”). to the Amended and Restated Advisory Services Agreement, Ms. Parshall will receive compensation of $500,000 for services we expect Ms. Parshall to provide in the fiscal year ending December 31, 2019, which amount may be increased (but will not exceed $750,000 for the year) if Ms. Parshall renders more services than currently expected. In addition, at the conclusion of each fiscal year, Ms. Parshall will be eligible for a bonus with a target of 35% of her fees with a personal performance factor to be approved by the Compensation Committee. Payment for services after 2019 will be set by mutual written agreement between the Company and Ms. Parshall.

Ms. Parshall will continue to serve on the board of directors of the Company and Akcea Therapeutics, Inc. (“Akcea”). Ms. Parshall will receive for her board service the same compensation as the Company and Akcea provide their other nonemployee directors. If in the future Ms. Parshall ends her board of director service for the Company, for 18 months following such date, the Company will pay Ms. Parshall’s COBRA premium payments, or if COBRA is not available, an amount equal to the cost of comparable health insurance coverage. The Amended and Restated Advisory Services Agreement will continue until terminated by the Company or Ms. Parshall upon 120 days’ advance written notice.

The foregoing summary of the Amended and Restated Advisory Services Agreement does not purport to be complete and is qualified in its entirety by reference to the Amended and Restated Advisory Services Agreement, a copy of which is attached hereto as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

(e)

Amendment and Restatement of Employee Stock Purchase Plan

On March 22, 2019, the Board adopted and approved an amendment and restatement of the Company’s 2000 Employee Stock Purchase Plan (the “ESPP”) to extend the ESPP so that it will terminate on March 21, 2029. No additional shares were added to the ESPP.

The foregoing description of the amended and restated ESPP does not purport to be complete and is qualified in its entirety by reference to the amended and restated ESPP, a copy of which is attached hereto as Exhibit 10.2 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

Amended and Restated Advisory Services Agreement dated March 22, 2019

Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan

Press Release dated March 25, 2019

IONIS PHARMACEUTICALS INC Exhibit
EX-10.1 2 ex10_1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDED AND RESTATED IONIS PHARMACEUTICALS,…
To view the full exhibit click here

About IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

An ad to help with our costs